Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases - PubMed

Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases

K Gijbels et al. J Clin Invest. 1994 Dec.

Abstract

Gelatinases, belonging to the matrix metalloproteases, contribute to tissue destruction in inflammatory demyelinating disorders of the central nervous system such as multiple sclerosis. We used experimental autoimmune encephalomyelitis (EAE) as an animal model to evaluate the effect of a hydroxamate matrix metalloprotease inhibitor (GM 6001) on inflammatory demyelination. A single dose of the inhibitor, given intraperitoneally, provided sufficient levels in the cerebrospinal fluid of animals with EAE to induce at least a partial inhibition of the gelatinase activity in the cerebrospinal fluid. When administered daily either from the time of disease induction or from the onset of clinical signs, GM 6001 suppressed the development or reversed clinical EAE in a dose-dependent way, respectively. Animals returned to the same clinical course as the nontreated group after cessation of treatment. Animals treated from the onset of clinical signs had normal permeability of the blood-brain barrier, compared with the enhanced permeability in nontreated animals. These results indicate that matrix metalloprotease inhibition can reverse ongoing EAE. This effect appears to be mediated mainly through restoration of the damaged blood-brain barrier in the inflammatory phase of the disease, since, the degree of demyelination and inflammation did not differ between the treatment groups.

Similar articles

• Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: Effects of darbepoetin alfa on TIMP-1 null and wild-type mice.

  Thorne M, Moore CS, Robertson GS. Thorne M, et al. J Neuroimmunol. 2009 Jun 25;211(1-2):92-100. doi: 10.1016/j.jneuroim.2009.04.003. Epub 2009 May 9. J Neuroimmunol. 2009. PMID: 19428125

• The interrelationship of alpha4 integrin and matrix metalloproteinase-2 in the pathogenesis of experimental autoimmune encephalomyelitis.

  Graesser D, Mahooti S, Haas T, Davis S, Clark RB, Madri JA. Graesser D, et al. Lab Invest. 1998 Nov;78(11):1445-58. Lab Invest. 1998. PMID: 9840619

• Angiopoietin-1 ameliorates inflammation-induced vascular leakage and improves functional impairment in a rat model of acute experimental autoimmune encephalomyelitis.

  Jiang H, Zhang F, Yang J, Han S. Jiang H, et al. Exp Neurol. 2014 Nov;261:245-57. doi: 10.1016/j.expneurol.2014.05.013. Epub 2014 May 20. Exp Neurol. 2014. PMID: 24852101

• Mechanisms and suppression of inflammatory demyelination.

  Norton WT, Brosnan CF, Cammer W, Goldmuntz EA. Norton WT, et al. Acta Neurobiol Exp (Wars). 1990;50(4-5):225-35. Acta Neurobiol Exp (Wars). 1990. PMID: 2130645 Review.

• Matrix metalloproteinases in inflammatory demyelination: targets for treatment.

  Kieseier BC, Seifert T, Giovannoni G, Hartung HP. Kieseier BC, et al. Neurology. 1999 Jul 13;53(1):20-5. doi: 10.1212/wnl.53.1.20. Neurology. 1999. PMID: 10408531 Review.

Cited by

• TIMP-1/MMP-9 imbalance in brain edema in rats with fulminant hepatic failure.

  Yamamoto S, Nguyen JH. Yamamoto S, et al. J Surg Res. 2006 Aug;134(2):307-14. doi: 10.1016/j.jss.2005.11.588. Epub 2006 Feb 20. J Surg Res. 2006. PMID: 16488444 Free PMC article.

• Hormone regulation of microglial cell activation: relevance to multiple sclerosis.

  Drew PD, Storer PD, Xu J, Chavis JA. Drew PD, et al. Brain Res Brain Res Rev. 2005 Apr;48(2):322-7. doi: 10.1016/j.brainresrev.2004.12.020. Epub 2005 Jan 19. Brain Res Brain Res Rev. 2005. PMID: 15850670 Free PMC article. Review.

• MMPs and ADAMs in neurological infectious diseases and multiple sclerosis.

  Muri L, Leppert D, Grandgirard D, Leib SL. Muri L, et al. Cell Mol Life Sci. 2019 Aug;76(16):3097-3116. doi: 10.1007/s00018-019-03174-6. Epub 2019 Jun 6. Cell Mol Life Sci. 2019. PMID: 31172218 Free PMC article. Review.

• Nuanced roles of cytokines in three major human brain disorders.

  Steinman L. Steinman L. J Clin Invest. 2008 Nov;118(11):3557-63. doi: 10.1172/JCI36532. J Clin Invest. 2008. PMID: 18982162 Free PMC article. Review.

• Matrix metalloproteinase inhibition enhances the rate of nerve regeneration in vivo by promoting dedifferentiation and mitosis of supporting schwann cells.

  Liu H, Kim Y, Chattopadhyay S, Shubayev I, Dolkas J, Shubayev VI. Liu H, et al. J Neuropathol Exp Neurol. 2010 Apr;69(4):386-95. doi: 10.1097/NEN.0b013e3181d68d12. J Neuropathol Exp Neurol. 2010. PMID: 20448483 Free PMC article.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Society for Clinical Investigation
  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information